A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 23.60%. However, over the past six months, we’ve seen a weaker performance of 30.80%. The price of ACAD fallen by 4.56% over the last 30 days. And in the last five days, it has surged by 4.32%.
Acadia Pharmaceuticals Inc’s stock market performance has been consistent.
52-week price history of ACAD Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Acadia Pharmaceuticals Inc’s current trading price is -10.11% away from its 52-week high, while its distance from the 52-week low is 69.25%. The stock’s price range for this period has been between $13.40 and $25.23. The Healthcare sector company’s shares saw a trading volume of about 1.15 million for the day, which was lower than the average daily volume of 2.08 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Acadia Pharmaceuticals Inc (ACAD) has experienced a quarterly rise of 32.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.80B and boasts a workforce of 654 employees.
How Moving Averages and Trading Volume Data Work Together
ACAD’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ACAD stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
